Clinical trials: Severe Pneumonia
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia, Viral, Covid19
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19
Introduction: SARS-CoV2 infection produces severe pneumonia with pulmonary alveolar collapse. There is no specific treatment to date.
- Conditions
- Pneumonia, Viral, Covid19, ARDS, Oxidative Stress
- Trial name
- ANTIOX-COVID (NCT04570254)
- Testing
- Vitamin C, Vitamin E, Melatonin
- Where
- Mexico
- Volunteers
- 110 people
- Sponsor
- Unidad Temporal COVID-19 en Centro Citibanamex
SARS-CoV Infection, Covid19
KIDney Injury in Times of COVID-19 (KIDCOV)
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable.
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury
- Trial name
- KIDCOV (NCT04705766)
- Testing
- Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Covid19, COVID-19
Tocilizumab in Coronavirus-19 Positive Patients
This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19.
- Conditions
- Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus
- Trial name
- NCT04423042
- Testing
- Tocilizumab
- Volunteers
- 30 people
- Sponsor
- University of Calgary
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
SARS-CoV Infection, COVID-19
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF).
- Trial name
- CONVINCE (NCT04516941)
- Testing
- Edoxaban Tablets, Colchicine Tablets
- Where
- 5 sites in Belgium, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pneumonia
Application of Serial Body Composition Change for Risk Prediction in Treating Patients With Severe Pneumonia
We hypothesize that serial changes of body composition in patients with pneumonia can help clinician to monitor prognosis. It was associated with underlying immune response.
- Trial name
- NCT04396522
- Testing
- noninvasively Bio-electrical Impedance Analysis (BIA)
- Where
- Taiwan
- Volunteers
- 194 people
- Sponsor
- Chang Gung Memorial Hospital
COVID-19, SARS-CoV Infection
Glycine Supplement for Severe COVID-19
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in…
- Conditions
- COVID-19, SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia
- Trial name
- NCT04443673
- Testing
- Glycine
- Where
- Mexico
- Volunteers
- 59 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
COVID-19, Convalescent Plasma Treatment
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica
Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection.
- Trial name
- NCT04644198
- Testing
- Convalescent Plasma Infusion
- Where
- Jamaica
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
COVID-19
Bioaerosol Sampling Device (BSD) Clinical Study
The goal of this clinical trial is to learn about the bioaerosol sampling device (BSD) and how it can sample patient bioaerosols (breath) and patient's nares for the detection of COVID-19 viral particles in patients seeking to be…
- Trial name
- NCT06047067
- Where
- 6 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Cantor BioConnect, Inc.
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pneumonia, Bacterial
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
- Trial name
- NCT00540072
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
COVID-19
Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19
The development of acute respiratory and renal failure of COVID-19 patients is associated with an excessive immune response and hyperproduction of anti-inflammatory cytokines, which leads to impaired endothelial function and a…
- Trial name
- NCT06402279
- Testing
- Efferon CT therapy
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Efferon JSC
Pneumonia
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
This study seeks to determine whether clinical outcome following initial treatment of severe pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin.
- Trial name
- NCT01399723
- Testing
- Amoxicillin, Benzyl penicillin
- Where
- 6 sites in Kenya
- Volunteers
- 561 people
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Severe Checkpoint Inhibitor Pneumonitis
The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia
This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of…
- Trial name
- NCT05899725
- Testing
- Corticosteroids, Corticosteroids and Ruxolitinib
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Mesenchymal Stem Cell, COVID-19 Pneumonia
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients
The goal of this randomized, controlled, open-labeled interventional clinical trial is to test the efficacy and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of severe and critical COVID-19 patients.
- Trial name
- NCT05682586
- Testing
- umbilical cord mesenchymal stem cells, paxlovid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Pneumocystis Jirovecii Pneumonia
Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia
Preclinical studies and retrospective clinical data suggest that adjunctive echinocandin therapy may improve outcomes in adults with severe Pneumocystis jirovecii pneumonia (PCP).
- Trial name
- ECHINO-PCP (NCT07900373)
- Testing
- Echinocandins
- Where
- Canada
- Volunteers
- 416 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.